Modality
Vaccine
MOA
KRASG12Ci
Target
FXIa
Pathway
Hedgehog
ASRA
Development Pipeline
Preclinical
Aug 2023
→ Jul 2029
PreclinicalCurrent
NCT08289538
2,570 pts·RA
2023-08→2025-09·Recruiting
NCT05598919
1,745 pts·AS
2025-08→2029-07·Terminated
4,315 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-176mo agoInterim· RA
2029-07-103.3y awayInterim· AS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2025-09-17 · 6mo ago
RA
Interim
2029-07-10 · 3.3y away
AS
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08289538 | Preclinical | RA | Recruiting | 2570 | BodyWt |
| NCT05598919 | Preclinical | AS | Terminated | 1745 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| BII-5449 | Biogen | Phase 3 | FXIa |